ArticleInternational journal of nanomedicine2025
Iron-Oxide Labeled Stem Cells with Specific Magnetic Occurrence for Effective in Mouse Model of Cisplatin-Induced Acute Kidney Injury.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing mesenchymal stem cell therapy for kidney diseases in companion animals: from mechanisms to clinical application.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is characterized by the abrupt loss of renal function and lack of curative therapies. Placental-derived mesenchymal stem cells (PL-MSCs) have shown promise in regenerative medicine, including in the treatment of AKI. However, optimizing the therapeutic effects of PL-MSCs remains a critical objective. Magnetic targeting is one potential avenue of optimization. Using iron oxide-labeled MSCs with an external magnetic field to increase cell homing ability may be an ideal method for improving the cell therapy effects in vivo. Methods: In this study, PL-MSCs were labeled with Fe Results: The study confirmed that MSCs or MSC-NP can significantly improve Cis-induced mRTEC injury. In addition, NP-labeled MSCs with an external magnetic field (magnetically-targeted MSCs) improved their homing to the kidney tissues in mice with AKI, resulting in enhanced kidney function compared with those of mice treated with MSC or NP-labeled MSC treatment alone. Moreover, magnetically-targeted MSCs alleviated renal injury through suppressing oxidative stress and inflammation, reducing cell apoptosis, and promoting cell proliferation. Conclusion: Magnetic targeting enhances the therapeutic effects of PL-MSCs on Cis-induced AKI in mice, suggesting that magnetically-targeted MSCs could serve as potential treatments for patients with Cis-induced AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.